Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Matthew C Hill is Chief Financial Officer at Apyx Medical. OQRO lists 2 transactions filed with the SEC under this name, the latest on Jun 15, 2026, each linked to the official Form 4.
Chief Financial Officer
Disclosures on record
2
Companies involved
1
Apyx MedicalAPYX
2 disclosures · Mar 2025 – Jun 2026 · 1 bought
Jun 11, 2026132Kdisclosed Jun 15
DetailsOfficial recordAug 13, 2024Bought~$6.8Kdisclosed Mar 3
DetailsAs of the latest filing on , Matthew C Hill reported holding 8,500 shares of Apyx Medical (APYX), worth about $22K at the last close of $3 (Nov 17, 2026).
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Apyx Medical APYX | 8,500 | 8,500 direct | $3 | $22K | Aug 13, 2024 |
Is this Matthew C Hill’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Matthew C Hill bought shares on the open market in 2021, 2023 and 2024, and has not bought since 2024 across 2 companies.
Matthew C Hill reported 5 open-market purchases and 0 sales since 2021; purchases in 3 different years, most recently 2024.
| Year | Bought | Sold |
|---|---|---|
| 2024 | $6K1×1 trade | — |
| 2023 | $5.5K1×1 trade | — |
| 2021 | $27K3×3 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Aug 13, 2024, Matthew C Hill reported holding 8,500 shares of Apyx Medical (APYX). At the last close of $3 on Nov 17, 2026, that is about $22K. This is the stake disclosed in filings, not a net worth.
Matthew C Hill bought shares on the open market in 2021, 2023 and 2024, and has not bought since 2024 across 2 companies.
In SEC filings since 2021: the latest open-market purchase is from 2024; no open-market sale is on record.
2 companies: Apyx Medical (APYX, 2023–2024), Pds Biotechnology (PDSB, 2021).
Matthew C Hill reported 3 open-market purchases and 0 sales here, 2021.
Matthew C Hill reported 2 open-market purchases and 0 sales here, 2023 to 2024.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.